NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $2.28 -1.27 (-35.77%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.34 +0.06 (+2.63%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Black Diamond Therapeutics Stock (NASDAQ:BDTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDTX alerts:Sign Up Key Stats Today's Range$2.25▼$3.0750-Day Range$2.03▼$3.6052-Week Range$1.93▼$4.94Volume8.36 million shsAverage Volume1.50 million shsMarket Capitalization$130.64 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingModerate Buy Company Overview Black Diamond Therapeutics, Inc. is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments. The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations. Black Diamond’s approach seeks to overcome resistance mechanisms that often limit the efficacy of existing therapies by focusing on mutation-specific vulnerabilities. Early-stage clinical trials for BDTX-189 are evaluating safety, pharmacokinetics, and anti-tumor activity in patients whose tumors harbor HER2 alterations. Founded in 2019 and listed on the Nasdaq under the ticker BDTX, Black Diamond Therapeutics combines scientific expertise with experience drawn from leading biopharmaceutical organizations. The company collaborates with academic centers and research institutions to advance its pipeline and is committed to delivering next-generation precision medicines to oncology patients worldwide.AI Generated. May Contain Errors. Read More Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreBDTX MarketRank™: Black Diamond Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 340th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBlack Diamond Therapeutics has a consensus price target of $10.00, representing about 338.6% upside from its current price of $2.28.Amount of Analyst CoverageBlack Diamond Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.58) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Black Diamond Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.61% of the float of Black Diamond Therapeutics has been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 5.26.Change versus previous monthShort interest in Black Diamond Therapeutics has recently decreased by 18.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment-0.36 News SentimentBlack Diamond Therapeutics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Black Diamond Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows7 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.29% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDTX Stock News HeadlinesBlack Diamond Therapeutics, Inc.1 hour ago | edition.cnn.comBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 22 at 8:00 AM | globenewswire.comThe SpaceX filing is public. The window is closing.SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.May 24 at 1:00 AM | Behind the Markets (Ad)Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsMay 21 at 5:13 PM | globenewswire.comBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLCMay 19, 2026 | globenewswire.comBlack Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth PlansMay 12, 2026 | finance.yahoo.comBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 7, 2026 | globenewswire.comBlack Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual MeetingApril 21, 2026 | quiverquant.comQSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.43 at the beginning of 2026. Since then, BDTX shares have decreased by 6.2% and is now trading at $2.28. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Thursday, May, 7th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $180 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 10,586,316 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Top institutional shareholders of Black Diamond Therapeutics include Renaissance Technologies LLC (2.87%), Dimensional Fund Advisors LP (2.27%), Arrowstreet Capital Limited Partnership (1.46%) and Empowered Funds LLC (0.40%). Insiders that own company stock include Ali Behbahani, Growth N V Biotech and David M Epstein. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), Compass Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR). Company Calendar Last Earnings5/07/2026Today5/24/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, BDTX's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for Black Diamond Therapeutics$10.00 High Price Target$14.00 Low Price Target$8.00 Potential Upside/Downside+338.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$22.37 million Net MarginsN/A Pretax Margin31.95% Return on Equity-30.18% Return on Assets-23.91% Debt Debt-to-Equity RatioN/A Current Ratio8.46 Quick Ratio8.46 Sales & Book Value Annual Sales$70 million Price / Sales1.87 Cash Flow$0.53 per share Price / Cash Flow4.32 Book Value$1.82 per share Price / Book1.25Miscellaneous Outstanding Shares57,300,000Free Float51,979,000Market Cap$130.64 million OptionableOptionable Beta3.34 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:BDTX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | SponsoredMusk’s Next $4 Trillion Takeover Target – It’s Stranger than you ThinkTech analyst Ian King - who called an early Tesla trade that returned up to 1,000% in just over a year - says ...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredYour computer is about to become a museum pieceFor 67 years, chip-making meant slicing a single silicon wafer into hundreds of pieces. Three companies just a...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
